ClinicalTrials.gg
CompletedNCT04146129Updated Jul 7, 2020

A Phase 1 Study of CDX-0159

A Phase 1 interventional study of CDX-0159 and Normal saline in Healthy Subjects, sponsored by Celldex Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study to determine the safety of CDX-0159 in healthy subjects.

Read the detailed description

CDX-0159 is a humanized monoclonal antibody that binds to a protein called KIT that is expressed on mast cells.

This study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 in healthy subjects.

02

Conditions studied

  • Healthy Subjects

Keywords

  • CDX-0159
03

In context

Lead sponsor

Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • An signed and dated by the subject.
  • Healthy volunteer aged 18-55.
  • In generally good health and without significant medical conditions based on physical exam, , and laboratory test results.
  • (BMI) ≥ 18.5 kg/m2 to ≤ 30 kg/m2
  • No medication other than mild analgesics, vitamins and mineral supplements or, oral
  • Both males and females of child bearing potential must agree to use a medically accepted contraceptive regimen during study and up to 150 days afterwards.
  • Not a current smoker (or regular user of any nicotine containing product).
  • Willing to follow all study rules

Key Exclusion Criteria:

  • Women who are pregnant or nursing
  • History of anaphylaxis, food allergies, or allergies (chronic or seasonal) requiring prescription medication
  • disorders requiring more than topical medication
  • History of asthma requiring the use of inhaled medication within the past 5 years.
  • Vaccination with within 4 weeks prior to study drug administration (subjects must agree to avoid vaccination during the study).
  • Positive urine test for alcohol and drugs of abuse.

Other Protocol defined inclusion and exclusion criteria could apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    CDX-0159

    Eligible subjects will receive a single dose of CDX-0159

    Drug: CDX-0159

  • Placebo comparator
    Normal saline

    Subjects assigned to receive placebo will receive a single dose of normal saline

    Drug: Normal saline

Interventions

  • Single dose of one of four dosages of CDX-0159

  • DrugNormal saline

    Single infusion of normal saline

06

What researchers measure

Primary outcomes

  1. Safety as assessed by CTCAE v5.0

    Safety of single, ascending doses of CDX-0159 as determined by percentage of participants with adverse events as assessed by CTCAE v5.0.

    Time frame: Day 1 to Day 43.

07

Study locations

1 site
  • Altasciences Clinical Kansas, Inc.
    Overland Park, Kansas 66212, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Apr 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2019
First posted
Oct 31, 2019
StartActual
Oct 29, 2019
Primary completionActual
Apr 6, 2020
CompletionActual
Jun 26, 2020
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04146129
Responsible party
Sponsor
First posted
Oct 31, 2019
Start date
Oct 29, 2019
Primary completion
Apr 6, 2020
Completion
Jun 26, 2020
Last update
Jul 7, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion